These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

183 related items for PubMed ID: 32063014

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. How to avoid nephrogenic systemic fibrosis: current guidelines in Europe and the United States.
    Thomsen HS.
    Radiol Clin North Am; 2009 Sep; 47(5):871-5, vii. PubMed ID: 19744601
    [Abstract] [Full Text] [Related]

  • 4. Prophylactic Hemodialysis for Protection Against Gadolinium-Induced Nephrogenic Systemic Fibrosis: A Doll's House.
    Yee J.
    Adv Chronic Kidney Dis; 2017 May; 24(3):133-135. PubMed ID: 28501073
    [No Abstract] [Full Text] [Related]

  • 5. Gadolinium and nephrogenic systemic fibrosis: have the alarm bells been silenced?
    Tamburrini O, Balducci A.
    Radiol Med; 2012 Feb; 117(1):1-5. PubMed ID: 22020430
    [Abstract] [Full Text] [Related]

  • 6. Nephrogenic systemic fibrosis: the need for accurate case reporting.
    Spinazzi A, Kirchin MA, Pirovano G.
    J Magn Reson Imaging; 2009 May; 29(5):1240; author reply 1241. PubMed ID: 19388104
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Nephrogenic systemic fibrosis.
    Weinreb JC, Kuo PH.
    Magn Reson Imaging Clin N Am; 2009 Feb; 17(1):159-67. PubMed ID: 19364606
    [Abstract] [Full Text] [Related]

  • 9. Nephrogenic systemic fibrosis and gadolinium: a cautionary tale in the molecular imaging era.
    Wang SC.
    J Med Imaging Radiat Oncol; 2008 Aug; 52(4):305-6. PubMed ID: 18811752
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. NSF prevention in clinical practice: summary of recommendations and guidelines in the United States, Canada, and Europe.
    Leiner T, Kucharczyk W.
    J Magn Reson Imaging; 2009 Dec; 30(6):1357-63. PubMed ID: 19937935
    [Abstract] [Full Text] [Related]

  • 13. Experimental studies investigating the pathophysiology of nephrogenic systemic fibrosis; what did we learn so far?
    Morcos SK.
    Eur Radiol; 2011 Mar; 21(3):496-500. PubMed ID: 20848109
    [No Abstract] [Full Text] [Related]

  • 14. Nephrogenic systemic fibrosis and class labeling of gadolinium-based contrast agents by the Food and Drug Administration.
    Yang L, Krefting I, Gorovets A, Marzella L, Kaiser J, Boucher R, Rieves D.
    Radiology; 2012 Oct; 265(1):248-53. PubMed ID: 22923714
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Updates to the ACR Manual on Contrast Media.
    Kodzwa R.
    Radiol Technol; 2017 Nov; 89(2):186-189. PubMed ID: 29298922
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Canadian Association of Radiologists national advisory on gadolinium administration and nephrogenic systemic fibrosis.
    Padilla-Thornton A, Zand KR, Barrett B, Stein L, Andrew G, Forster BB.
    Can Assoc Radiol J; 2008 Dec; 59(5):237-40. PubMed ID: 19385151
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.